Craig Underhill
Overview
Explore the profile of Craig Underhill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tie J, Wang Y, Lo S, Lahouel K, Cohen J, Wong R, et al.
Nat Med
. 2025 Mar;
PMID: 40055522
Early data from the DYNAMIC study of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy (ACT) versus standard approach met its primary outcome demonstrating reduced ACT use without compromising 2-year recurrence-free survival...
2.
Underhill C, Sabesan S, Wilson E
Lancet Oncol
. 2024 Dec;
25(12):e625.
PMID: 39637897
No abstract available.
3.
Glewis S, Lingaratnam S, Lee B, Campbell I, IJzerman M, Fagery M, et al.
Clin Transl Sci
. 2024 Nov;
17(12):e70083.
PMID: 39614408
PACIFIC-PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype-guided dosing on severe fluoropyrimidine (FP) and irinotecan-related toxicities and hospitalizations, compared to historical...
4.
Loft M, Wong V, Kosmider S, Wong R, Shapiro J, Hong W, et al.
Intern Med J
. 2024 Nov;
55(1):41-46.
PMID: 39555636
Background: Immunotherapy has emerged as a standard treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Pembrolizumab became widely available as a first-line (1L) option in Australia following the...
5.
Tissera S, Billah B, Brand M, Karim M, Antippa P, Blum R, et al.
Clin Lung Cancer
. 2024 Sep;
25(8):e466-e478.
PMID: 39304361
Background: Lung cancer in Australia contributes 9% of all new cancer diagnoses and is the leading cause of cancer death and burden. Clinical practice guidelines provide evidence-based treatment recommendations for...
6.
Frentzas S, Mislang A, Lemech C, Nagrial A, Underhill C, Wang W, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38642937
Background: Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescimab is...
7.
Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak B, et al.
Nat Med
. 2024 Mar;
30(3):797-809.
PMID: 38429524
Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies...
8.
Underhill C, Freeman J, Dixon J, Buzza M, Long D, Burbury K, et al.
JAMA Oncol
. 2024 Feb;
10(4):526-530.
PMID: 38358756
Importance: The need to maintain clinical trial recruitment during the COVID-19 pandemic has precipitated the rapid uptake of digital health for the conduct of clinical trials. Different terms are used...
9.
Alexander M, Collins I, Abraham P, Underhill C, Harris S, Torres J, et al.
Intern Med J
. 2023 Dec;
53(12):2346-2349.
PMID: 38130050
This cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist...
10.
Conduit C, Davis I, Goh J, Kichenadasse G, Gurney H, Harris C, et al.
BJU Int
. 2023 Nov;
133 Suppl 3:57-67.
PMID: 37986556
Objective: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-cell renal cell carcinoma (nccRCC). Materials And Methods: UNISoN...